Ultragenyx报告说,GTX-102针对天使综合症治疗的第1/2阶段取得了积极成果。 Ultragenyx reports positive Phase 1/2 results for GTX-102, targeting Angelman syndrome treatment.

Ultragenyx制药公司宣布GTX-102(一种旨在治疗Angelman综合症 -- -- 一种罕见的神经基因紊乱症 -- -- 的抗血清寡核分裂化物)第1/2阶段有希望的结果。 Ultragenyx Pharmaceutical announced promising Phase 1/2 results for GTX-102, an antisense oligonucleotide aimed at treating Angelman syndrome, a rare neurogenetic disorder. 数据表明在关键认知领域有所改进,支持即将进行的第三阶段研究,该研究计划招收约120名病人。 Data indicate improvements in key cognitive areas, supporting the upcoming Phase 3 Aspire study, which plans to enroll around 120 patients. 该研究将侧重于认知增强,并收到了监管机构为其潜在益处作出的多次指定。 The study will focus on cognitive enhancements and has received multiple designations from regulatory bodies for its potential benefits.

文章

Eagle Tribune

Market Screener

MENAFN

-- 显示更少 --

延伸阅读

相关故事